Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort

PURPOSE: Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as first-line has positioned T-DM1 into second-line, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Moinard-Butot, Fabien, Saint-Martin, Caroline, Pflumio, Carole, Carton, Matthieu, Jacot, William, Cottu, Paul-Henri, Diéras, Véronique, Dalenc, Florence, Goncalves, Anthony, Debled, Marc, Patsouris, Anne, Mouret-Reynier, Marie-Ange, Vanlemmens, Laurence, Leheurteur, Marianne, Emile, George, Ferrero, Jean-Marc, Desmoulins, Isabelle, Uwer, Lionel, Eymard, Jean-Christophe, Cheaib, Bianca, Courtinard, Coralie, Bachelot, Thomas, Chevrot, Michaël, Petit, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927850/
https://www.ncbi.nlm.nih.gov/pubmed/35299035
http://dx.doi.org/10.1016/j.breast.2022.03.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927850/
https://www.ncbi.nlm.nih.gov/pubmed/35299035
http://dx.doi.org/10.1016/j.breast.2022.03.004

Ejemplares similares